Jaguar Animal Health Appoints Leading Oncologist and Drug Development Executive as Chief Scientific Officer

Dr. Roger Waltzman to Lead Development Teams for Jaguar’s SB-300 and
Canalevia Drug Product Candidates

SAN FRANCISCO–(BUSINESS WIRE)–Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an
animal health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and production
animals, foals, and high value horses, announced today that it has
appointed Dr. Roger Waltzman as Chief Scientific Officer.

Dr. Waltzman is a human medical oncologist and experienced
drug-development executive. He spent over 10 years in academic clinical
oncology practice at Memorial Sloan-Kettering, Mount Sinai, and Saint
Vincent hospitals in New York, and nine years in drug development with
Novartis Pharmaceuticals, leading successful NDA and sNDA filings for
Glivec, Tasigna, and Jakavi, and serving most recently as Head of
Development for anti-malarials at Novartis. Dr. Waltzman earned his MD
degree from Brown University School of Medicine and completed internal
medicine training at Beth Israel Hospital in Boston, as well as a
fellowship in hematology/oncology at Memorial Sloan-Kettering Cancer
Center in New York City. He is board certified in medical oncology. Dr.
Waltzman’s research has been published in the New England Journal of
Medicine, Journal of Clinical Oncology
, Haematologica, Cancer
Investigation
, Gynecologic Oncology, Supportive Cancer
Therapeutics, Diseases of the Colon and Rectum, Oncologist,
Seminars
in Hematology,
Journal of the National Cancer Comprehensive
Network, Leukemia Research
, Cancer and the Journal of
Supportive Oncology
.

Dr. Waltzman will lead product development efforts for the commercial
formulation of SB-300, Jaguar’s drug product candidate for equine
gastric ulcer syndrome, and lead development efforts in
chemotherapy-induced diarrhea (“CID”) for Canalevia, the
Company’s drug product candidate that is currently being assessed, in a
final Jaguar field study, for acute diarrhea in dogs. Tyrosine kinase
inhibitors are utilized in long-term cancer management in dogs, with
some dogs experiencing dose-limiting diarrhea.

“We are very happy to have a drug development leader of Roger’s stature
join the Jaguar management team as we focus on preparations for the
expected commercial launch of SB-300 and Canalevia,” stated
Lisa Conte, Jaguar’s president and CEO. “Roger brings a wealth of
knowledge to the table, including experience overseeing an
investigator-initiated program for Napo Pharmaceuticals (“Napo”) for CID
that is analogous in mechanistic rationale to the CID program Jaguar
will be looking at for chronic diarrhea management in dogs. He is also
well-versed with the manufacturing, supply, and novel mechanism of
action of Croton lechleri-derived anti-secretory products.”

Jaguar and Napo have been engaged in exploratory discussions since
February 2016 regarding a potential merger and/or other ways to
cooperate with their respective business endeavors. Jaguar holds the
exclusive global rights to Canalevia and SB-300 under
license from Napo. It is expected that Dr. Waltzman will continue to
contribute to Napo’s development efforts through a service agreement
between Napo and Jaguar.

About Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals, foals, and high value horses.
Canalevia is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea in
dogs. SB-300 is Jaguar’s prescription drug product candidate for the
treatment of gastrointestinal ulcers in horses. Canalevia
and SB-300 contain ingredients isolated and purified from the Croton
lechleri
tree, which is sustainably harvested. Neonorm
Calf and Neonorm Foal are the Company’s lead
non-prescription products. Neonorm is a standardized
botanical extract derived from the Croton lechleri tree. Canalevia
and Neonorm are distinct products that act at the same last
step in a physiological pathway generally present in mammals. Jaguar has
nine active investigational new animal drug applications, or INADs,
filed with the FDA and intends to develop species-specific formulations
of Neonorm in six additional target species, formulations of
SB-300 in horses, and Canalevia for cats and dogs.

For more information, please visit www.jaguaranimalhealth.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the expected commercial
launch of SB-300 and Canalevia, the expectation that Dr.
Waltzman will continue to contribute to Napo’s development efforts
through a service agreement between Napo and Jaguar, the Company’s
intention to develop formulations of SB-300 in horses and
species-specific formulations of Neonorm in additional
target species, and the Company’s plan to develop formulations of
Canalevia for cats and dogs. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,” “should,”
“expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”
or “continue” or the negative of these terms or other similar
expressions. The forward-looking statements in this release are only
predictions. Jaguar has based these forward-looking statements largely
on its current expectations and projections about future events. These
forward-looking statements speak only as of the date of this release and
are subject to a number of risks, uncertainties and assumptions, some of
which cannot be predicted or quantified and some of which are beyond
Jaguar’s control. Except as required by applicable law, Jaguar does not
plan to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information, future
events, changed circumstances or otherwise.

Jaguar-JAGX

Contacts

KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com